Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Recruiting now Phase 2 NCT06947993
Run by Novartis Pharmaceuticals · for 18 to 100 · All sexes
What this study is about
This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).
Who can join (things the study team will check)
✅ You may be able to join if…
- Able and willing to sign the informed consent (IC)
- Patients with a diagnosis of AD and onset of disease for at least 1 year
- Moderate to severe AD
🚫 You may not be able to join if…
- Participants with a clinically significant medical condition or infectious disease (specified in sub-protocol)
- Participants with clinically significant abnormal hematology, clinical chemistry, or urine test results or clinically significant abnormal ECG
- Participant with any other active inflammatory skin disease
- Participants with any chronic, uncontrolled medical condition, which would put the participant at increased risk during the study (e.g., uncontrolled: diabetes, hypertension)
- Participants with any clinically unstable disease states that would likely require systemic corticosteroids (e.g., uncontrolled asthma) Additional inclusion and exclusion criteria may apply depending on the intervention specific requirements
Where this trial is running
- Novartis Investigative Site, Birmingham, Alabama, United States
- Novartis Investigative Site, Birmingham, Alabama, United States
- Novartis Investigative Site, Fort Smith, Arkansas, United States
- Novartis Investigative Site, Fountain Valley, California, United States
- Novartis Investigative Site, Los Angeles, California, United States
- Novartis Investigative Site, Sacramento, California, United States
- Novartis Investigative Site, Santa Ana, California, United States
- Novartis Investigative Site, Santa Monica, California, United States
- Novartis Investigative Site, Washington D.C., District of Columbia, United States
- Novartis Investigative Site, Miami, Florida, United States
- Novartis Investigative Site, Atlanta, Georgia, United States
- Novartis Investigative Site, Macon, Georgia, United States
+ 87 more sites.
Who to contact
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06947993.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.